Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis

For patients with advanced thymic epithelial tumours (TET), there is no standard second-line treatment after platinum-based chemotherapy. Although immune checkpoint blockers (ICB) are a potential treatment strategy, their efficacy seems limited with an increased risk of immune-related adverse events...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of cancer (1990) Vol. 180; pp. 117 - 124
Main Authors:	Remon, Jordi, Villacampa, Guillermo, Facchinetti, Francesco, Di Maio, Massimo, Marcuse, Florit, Tiseo, Marcello, Hochstenbag, Monique, Hendriks, Lizza E.L., Besse, Benjamin
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01-02-2023 Elsevier Science Ltd
Subjects:	Advanced thymic epithelial tumours Atezolizumab Avelumab Cancer Chemotherapy Clinical trials Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Effectiveness Humans Immune checkpoint Immune checkpoint blockers Immune Checkpoint Inhibitors - adverse effects Meta-analysis Metastases Metastasis Neoplasms, Glandular and Epithelial - drug therapy Neoplasms, Glandular and Epithelial - pathology Nivolumab Patients Pembrolizumab Platinum Platinum - therapeutic use Strategy Survival Thymoma Thymoma - drug therapy Thymus Thymus Neoplasms - drug therapy Thymus Neoplasms - pathology Toxicity Tumors Immune checkpoint blockers Avelumab Pembrolizumab Nivolumab Advanced thymic epithelial tumours Atezolizumab
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!